Zejula

Merck's $169M Investment in PARP1 inhibitors Challenges AstraZeneca & Gilead

Merck Invests $169M in Selective PARP1 Drug, Intensifying Competition with AstraZeneca and Gilead

Anika Sharma

Merck KGaA is making a strategic move in the field of PARP inhibitors, investing a substantial 160 million euros ($169 ...